Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...

Endo shareholders will receive $80 million in cash and own 49.9% of the combined company. The merged firm expects $3.6 billion in 2025 revenue and $1.2 billion in adjusted EBITDA. Feel unsure ...

The combined company will be headquartered in Dublin, Ireland, where Mallinckrodt’s HQ is based, following the close of the merger agreement. Mallinckrodt and Endo said the location of the ...

Specialty pharmaceutical companies Endo, Inc. (OTC:ENDPQ) and Mallinckrodt (OTC:MNKTQ) announced Thursday plans to combine in a stock and cash transaction worth $6.7B, creating a public firm ...

Upon completion of the merger, Olafsson will become CEO of the combined company, and Paul Efron, a member of the Endo board of directors, will serve as chairman. Scott Hirsch, interim CEO of Endo ...

Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Endo, Inc. (OTC: NDOI) and Mallinckrodt plc. Under the terms of the proposed ...

Endo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as ...